Research Appraisalother

Enhanced ResU-Net for brain tumor segmentation using EfficientNetB0, channel attention, and ASPP

Biomedical physics & engineering expressBehzadpour, Majid, Azizi, Ebrahim, Ortiz, Bengie L et al.5 May 2026DOI

Clinical Snapshot

70CEBM
Evidence: Moderateother

PICO Framework

P — PopulationBrain tumor patients with MRI scans from TCGA Low Grade Glioma and BraTS-2020 datasets
I — InterventionEnhanced ResU-Net architecture with EfficientNetB0 encoder, channel attention mechanism, and ASPP module
C — ComparatorBaseline ResU-Net and EfficientNet variant, compared against state-of-the-art segmentation methods
O — OutcomesDice similarity coefficient, HD95 scores for whole tumor and tumor core segmentation accuracy

Bottom Line

This technical study presents an enhanced deep learning architecture for automated brain tumor segmentation, achieving competitive performance on benchmark datasets with Dice coefficients of 0.903 for whole tumor segmentation. While the architectural improvements show promise, the study lacks statistical rigor with no confidence intervals or significance testing reported. The clinical applicability remains uncertain without real-world validation, cost-effectiveness analysis, or integration studies. For Australian practice, this represents early-stage research that would require substantial additional validation, regulatory approval, and workflow integration studies before clinical implementation. Clinicians should view this as promising foundational research rather than ready-for-practice technology.

Evidence: Moderate

Key Findings

  • P Value: Not reported

  • Effect Size: Dice coefficient: 0.903 (whole tumor), 0.851 (tumor core)

  • Primary Outcome: Dice similarity coefficient for brain tumor segmentation

  • Nnt Or Sensitivity: HD95 scores: 9.43 (whole tumor), 3.54 (tumor core)

  • Confidence Interval: Not reported

Clinical Application

Requires specialized computational infrastructure and integration with existing imaging workflows Would need validation with Australian imaging protocols and TGA approval for clinical implementation. Integration with existing radiology information systems would be essential Patients requiring brain tumor segmentation for diagnosis and treatment planning

Abstract

Accurate and efficient segmentation of brain tumors is critical for diagnosis, treatment planning, and monitoring in clinical practice. In this study, we present an enhanced ResU-Net architecture for automatic brain tumor segmentation, integrating an EfficientNetB0 encoder, a channel attention mechanism, and an atrous spatial pyramid pooling (ASPP) module. The EfficientNetB0 encoder leverages pre-trained features to improve feature extraction efficiency, while the channel attention mechanism enhances the model's focus on tumor-relevant features. ASPP enables multi-scale contextual learning, which is crucial for handling tumors of varying sizes and shapes. The proposed model was evaluated on two benchmark datasets: The Cancer Genome Atlas Low Grade Glioma and brain tumor segmentation (BraTS-2020). Experimental results demonstrate that our method consistently outperforms the baseline ResU-Net and its EfficientNet variant, achieving dice similarity coefficient of 0.903 and 0.851, and HD95 scores of 9.43 and 3.54 for whole tumor and tumor core (TC) regions on the BraTS 2020 dataset, respectively. Compared to state-of-the-art methods, our approach shows competitive performance, particularly in whole tumor and TC segmentation. These results indicate that combining a powerful encoder with attention mechanisms and ASPP can significantly enhance BraTS performance. The proposed approach holds promise for further optimization and application in other medical image segmentation tasks.

References

  1. 1.Behzadpour, M., Azizi, E., Ortiz, B. L., & Wu, K. (2024). Enhanced ResU-Net for brain tumor segmentation using EfficientNetB0, channel attention, and ASPP. Biomedical Physics & Engineering Express. https://doi.org/10.1088/2057-1976/ae6459
Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service